Linee guida AIAC 2010 per la gestione e il trattamento della - Stopfa

289. Pritchett EL, Page RL, Carlson M, Undesser
K, Fava G; Rythmol Atrial Fibrillation
Trial (RAFT) Investigators. Efficacy and safety
of sustained-release of propafenone
(propafenone SR) for patients with atrial fibrillation.
Am J Cardiol 2003;92:941-6.
290. Wanless RS, Anderson K, Joy M,
Joseph SP. Multicenter comparative study
of the efficacy and safety of sotalol in the
prophylactic treatment of patients with
paroxysmal supraventricular tachyarrhythmias.
Am Heart J 1997;133:441-6.
291. Benditt DG, Williams JH, Jin J, et al.
Maintenance of sinus rhythm with oral d,lsotalol
therapy in patients with symptomatic
atrial fibrillation and/or atrial flutter. d,l-Sotalol
Atrial Fibrillation/Flutter Study Group.
Am J Cardiol 1999;84:270-7.
292. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg
N. Sotalol versus quinidine for
the maintenance of sinus rhythm after direct
current conversion of atrial fibrillation. Circulation
1990;82:1932-9.
293. Kochiadakis GE, Igoumenidis NE,
Hamilos ME, et al. Sotalol versus propa -
fenone for long-term maintenance of normal
sinus rhythm in patients with recurrent
symptomatic atrial fibrillation. Am J Cardiol
2004;94:1563-6.
294. Steeds RP, Birchall AS, Smith M, Channer
KS. An open label, randomised,
crossover study comparing sotalol and
atenolol in the treatment of symptomatic
paroxysmal atrial fibrillation. Heart 1999;82:
170-5.
295. Vitolo E, Tronci M, La Rovere MT, Rumolo
R, Morabito A. Amiodarone versus
quinidine in the prophylaxis of atrial fibrillation.
Acta Cardiol 1981;36:431-44.
296. Roy D, Talajic M, Dorian P, et al. Amiodarone
to prevent recurrences of atrial fibrillation.
Canadian Trial of Atrial Fibrillation
Investigators. N Engl J Med 2000;342:913-
20.
297. Vorperian VR, Havighurst TC, Miller S,
January CT. Adverse effects of low dose
amiodarone: a meta-analysis. J Am Coll Cardiol
1997;30:791-8.
298. Vassallo P, Trohman RG. Prescribing
amiodarone: an evidence-based review of
clinical indications. JAMA 2007;298:1312-
22.
299. Goldschlager N, Epstein AE, Naccarelli
GV, et al.; Practice Guidelines Sub-committee,
North American Society of Pacing and
Electrophysiology (HRS). A practical guide
for clinicians who treat patients with amiodarone:
2007. Heart Rhythm 2007;4:1250-
9.
300. Kuhlkamp V, Schirdewan A, Stangl K,
Homberg M, Ploch M, Beck OA. Use of
metoprolol CR/XL to maintain sinus rhythm
after conversion from persistent atrial fibrillation:
a randomized, double-blind, placebocontrolled
study. J Am Coll Cardiol 2000;36:
139-46.
301. Murgatroyd FD, Gibson SM, Baiyan X,
et al. Double-blind placebo-controlled trial
LINEE GUIDA AIAC 2010 PER LA GESTIONE EIL TRATTAMENTO DELLA FA
of digoxin in symptomatic paroxysmal atrial
fibrillation. Circulation 1999;99:2765-70.
302. Patel C, Yan GX, Kowey PR. Dro -
nedarone. Circulation 2009;120:636-44.
303. Touboul P, Brugada J, Capucci A, Crijns
HJ, Edvardsson N, Hohnloser SH.
Dronedarone for prevention of atrial fibrillation:
a dose-ranging study. Eur Heart J
2003;24:1481-7.
304. Singh BN, Connolly SJ, Crijns HJ, et al.;
EURIDIS and ADONIS Investigators. Dro -
nedarone for maintenance of sinus rhythm
in atrial fibrillation or flutter. N Engl J Med
2007;357:987-99.
305. Davy JM, Herold H, Hoglund C, et al.;
ERATO Study Investigators. Dronedarone for
the control of ventricular rate in permanent
atrial fibrillation: the Efficacy and safety of
dRonedArone for the cOntrol of ventricular
rate during atrial fibrillation (ERATO) study.
Am Heart J 2008;156:527.e1-9.
306. Hohnloser SH, Crijns HJ, van Eickels M,
et al.; ATHENA Investigators. Effect of
dronedarone on cardiovascular events in
atrial fibrillation. N Engl J Med 2009;360:
668-78.
307. Connolly SJ, Crijns HJ, Torp-Pedersen
C, et al.; ATHENA Investigators. Analysis of
stroke in ATHENA: a placebo-controlled,
double-blind, parallel-arm trial to assess the
efficacy of dronedarone 400 mg bid for the
prevention of cardiovascular hospitalization
or death for any cause in patients with atrial
fibrillation/atrial flutter. Circulation 2009;
120:1174-80.
308. Le Heuzey JY, De Ferrari GM, Radzik D,
Santini M, Zhu J, Davy JM. A short-term,
randomized, double-blind, parallel-group
study to evaluate the efficacy and safety of
dronedarone versus amiodarone in patients
with persistent atrial fibrillation: the
DIONYSOS study. J Cardiovasc Electrophysiol
2010;21:597-605.
309. Kober L, Torp-Pedersen C, McMurray
JJ, et al.; Dronedarone Study Group. Increased
mortality after dronedarone therapy
for severe heart failure. N Engl J Med
2008;358:2678-87.
310. Hohnloser SH, Crijns HJ, van Eickels M,
et al.; ATHENA Investigators. Dronedarone
in patients with congestive heart failure: insights
from ATHENA. Eur Heart J 2010;31:
1717-21.
311. Cosio FG, Aliot E, Botto GL, et al. Delayed
rhythm control of atrial fibrillation may
be a cause of failure to prevent recurrences:
reasons for change to active antiarrhythmic
treatment at the time of the first detected
episode. Europace 2008;10:21-7.
312. Schwartz JB, Keefe D, Harrison DC.
Adverse effects of antiarrhythmic drugs.
Drugs 1981;21:23-45.
313. Maisel WH, Kuntz KM, Reimold SC, et
al. Risk of initiating antiarrhythmic drug therapy
for atrial fibrillation in patients admitted
to a university hospital. Ann Intern Med
1997;127:281-4.
314. Kaufman ES, Zimmermann PA, Wang
T, et al.; Atrial Fibrillation Follow-up Investigation
of Rhythm Management Investigators.
Risk of proarrhythmic events in the
Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) study: a
multivariate analysis. J Am Coll Cardiol
2004;44:1276-82.
315. Simons GR, Eisenstein EL, Shaw LJ,
Mark DB, Pritchett EL. Cost-effectiveness of
inpatient initiation of antiarrhythmic therapy
for supraventricular tachycardias. Am J Cardiol
1997;80:1551-7.
316. Ommen SR, Odell JA, Stanton MS.
Atrial arrhythmias after cardiothoracic surgery.
N Engl J Med 1997;336:1429-34.
317. Dixon FE, Genton E, Vacek JL, Moore
CB, Landry J. Factors predisposing to
supraventricular tachyarrhythmias after
coronary artery bypass grafting. Am J Cardiol
1986;58:476-8.
318. Leitch JW, Thomson D, Baird DK, Harris
PJ. The importance of age as a predictor
of atrial fibrillation and flutter after coronary
artery bypass grafting. J Thorac Cardiovasc
Surg 1990;100:338-42.
319. Caretta Q, Mercanti CA, De Nardo D,
et al. Ventricular conduction defects and
atrial fibrillation after coronary artery bypass
grafting. Multivariate analysis of preoperative,
intraoperative and postoperative
variables. Eur Heart J 1991;12:1107-11.
320. Aranki SF, Shaw DP, Adams DH, et al.
Predictors of atrial fibrillation after coronary
artery surgery. Current trends and impact on
hospital resources. Circulation 1996;94:390-
7.
321. Kernis SJ, Nkorno VT, Messika-Zeitoun
D, et al. Atrial fibrillation after surgical correction
of mitral regurgitation in sinus
rhythm: incidence, outcome, and determinants.
Circulation 2004;110:2320-5.
322. Beggs VL, Birkemeyer NJ, Nugent WC,
Dacey LJ, O’Connor GT. Factors related to
rehospitalization within thirty days of discharge
after coronary artery bypass grafting.
Best Pract Benchmarking Healthc 1996;1:
180-6.
323. Cioffi G, Mureddu G, Cemin C, et al.
Characterization of post-discharge atrial fibrillation
following open-heart surgery in uncomplicated
patients referred to an early rehabilitation
program. Ital Heart J 2001;2:
519-28.
324. Antonelli D, Peres D, Freedberg NA,
Feldman A, Rosenfeld T. Incidence of postdischarge
symptomatic paroxysmal atrial fibrillation
in patients who underwent coronary
artery bypass graft: long-term follow-up.
Pacing Clin Electrophysiol 2004;27:365-7.
325. Behar S, Zahavi Z, Goldbourt U, Rei -
cher-Reiss H. Long-term prognosis of patients
with paroxysmal atrial fibrillation complicating
acute myocardial infarction. SPRINT
Study Group. Eur Heart J 1992;13:45-50.
326. Eldar M, Canetti M, Rotstein Z, et al.
Significance of paroxysmal atrial fibrillation
complicating acute myocardial infarction in
the thrombolytic era. SPRINT and Throm-
G ITAL CARDIOL | VOL 12 | SUPPL 1 AL N 1 2011
57